Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning Regimens for HSCT in RRMS
NCT05482542Withdrawn
- Sponsor
- Scripps Health
- Start
- Jan 2023
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial in multiple sclerosis (MS) comparing Cyclophosphamide/ATG with Cyclophosphamide/Rituximab (2 arms). Primary endpoint: Durability of remission between two arms at 5 years. Planned start Jan 2023; status: withdrawn.
02
Drugs
rituximabantithymocyte globulin rabbit
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05482542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482542.